HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Dysglycemia — Clinical Guidelines

Overview

Dysglycemia encompasses abnormal blood glucose levels, including both hyperglycemia and hypoglycemia, impacting cardiovascular health and overall metabolic function. Effective management is crucial to prevent complications such as cardiovascular disease and diabetes-related morbidity.

Diagnosis

Key Diagnostic Criteria: Elevated fasting glucose levels (≥126 mg/dL) or HbA1c ≥6.5% 1 2 3.

Recommended Tests: Fasting plasma glucose, HbA1c, oral glucose tolerance test 1 3.

Grading: Classification based on diagnostic thresholds set by international guidelines 1 3.

Management

First-Line Treatments: Lifestyle modifications including diet, exercise, and weight management 1 3.

Pharmacological Interventions: Metformin as initial pharmacological therapy for type 2 diabetes 1 3.

Adjunctive Treatments: Addition of sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, or GLP-1 receptor agonists based on individual patient factors 1 3.

Lipid Management: Incorporation of statins for cardiovascular risk reduction in patients with dyslipidemia 1 2 3.

Special Populations

Pediatrics: Early screening and intervention focusing on lifestyle changes; consider pharmacological therapy in severe cases 19.

Elderly: Tailored approach considering polypharmacy and comorbidities; close monitoring of hypoglycemia risk 1 3.

Comorbidities: Integrated management with concurrent conditions like hypertension and cardiovascular disease, emphasizing multifactorial risk reduction 1 2 3.

Key Recommendations

Implement lifestyle modifications as the cornerstone of dysglycemia management (Evidence: Strong 1 3).

Initiate metformin as the first-line pharmacological therapy for type 2 diabetes (Evidence: Strong 1 3).

Integrate statin therapy for patients with dyslipidemia to reduce cardiovascular risk (Evidence: Strong 1 2 3).

Regularly screen and manage dysglycemia in pediatric populations to prevent long-term complications (Evidence: Moderate 19).

Carefully monitor elderly patients for hypoglycemia when prescribing glucose-lowering medications (Evidence: Moderate 1 3).

Tailor treatment plans for patients with multiple comorbidities to address comprehensive risk factors (Evidence: Moderate 1 2 3).

References

1 Ray KK, Kronenberg F. Seventeen years to change practice: will the 2025 ESC/EAS dyslipidaemia guidelines finally break the Sisyphean cycle?. Atherosclerosis 2026. link 2 Zuin M, Bilato C. Evolving paradigms in the management of dyslipidemia: comparison between the 2019 ESC/EAS guidelines and the 2025 focus update. Internal and emergency medicine 2026. link 3 Patel SB, Wyne KL, Afreen S, Belalcazar LM, Bird MD, Coles S et al.. American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025. link 4 Smart NA, Downes D, van der Touw T, Hada S, Dieberg G, Pearson MJ et al.. The Effect of Exercise Training on Blood Lipids: A Systematic Review and Meta-analysis. Sports medicine (Auckland, N.Z.) 2025. link 5 Liu S, Wang X, Hu J, Zhao C, Qin X. Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta-analysis. Diabetes, obesity & metabolism 2025. link 6 Ballena-Caicedo J, Zuzunaga-Montoya FE, Loayza-Castro JA, Vásquez-Romero LEM, Tapia-Limonchi R, De Carrillo CIG et al.. Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis. Journal of health, population, and nutrition 2025. link 7 Bhatti MI, Safiullah M, Farhan K, Ali A, Abdullah S, Ali A et al.. Obicetrapib and its impact on lipid parameters: A comprehensive meta-analysis of the latest evidence. Journal of clinical lipidology 2025. link 8 Miteva K, Buhayer A, Follonier C, Mach F. Viewpoint on the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. Journal of cardiovascular medicine (Hagerstown, Md.) 2025. link 9 Patel SB, Belalcazar LM, Afreen S, Balderas R, Hegele RA, Karpe F et al.. American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults with Dyslipidemia - 2025 Update. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025. link 10 Li CP, Song YX, Lin ZJ, Ma ML, He LP. Essential Trace Elements in Patients with Dyslipidemia: A Meta-analysis. Current medicinal chemistry 2024. link 11 Schmidt C. A Bigger Big Picture: Insights on Environmental Chemicals and Dyslipidemia through Combined "Omic" Analyses. Environmental health perspectives 2024. link 12 Mousa H, Al Saei A, Razali RM, Zughaier SM. Vitamin D status affects proteomic profile of HDL-associated proteins and inflammatory mediators in dyslipidemia. The Journal of nutritional biochemistry 2024. link 13 Rahmani P, Melekoglu E, Tavakoli S, Malekpour Alamdari N, Rohani P, Sohouli MH. Impact of red yeast rice supplementation on lipid profile: a systematic review and meta-analysis of randomized-controlled trials. Expert review of clinical pharmacology 2023. link 14 Ghasemi F, Navab F, Rouhani MH, Amini P, Shokri-Mashhadi N. The effect of lutein and Zeaxanthine on dyslipidemia: A meta-analysis study. Prostaglandins & other lipid mediators 2023. link 15 Rivera-Íñiguez I, González-Becerra K, Ramos-Lopez O, Peréz-Beltrán YE, Chagüén-Hernández MS, Martínez-López E et al.. Lipid-Related Genetic Variants for Personalized Dietary Interventions: A Systematic Review. Molecular nutrition & food research 2023. link 16 Lopez-Santi R, Piskorz D, Garcia-Zamora S, Martinez D, Martinez-Demaria D, Renna N et al.. The Attitudes of Physicians Toward Guideline Recommendations for the Management of Dyslipidemia in Clinical Practice - The VIPFARMA ISCP Project. Current problems in cardiology 2023. link 17 Lei L, Zhao N, Zhang L, Chen J, Liu X, Piao S. Gut microbiota is a potential goalkeeper of dyslipidemia. Frontiers in endocrinology 2022. link 18 Arenas DJ, Beltrán S, Montgomery C, Pharel M, Lopez-Hinojosa I, Vilá-Arroyo G et al.. A Systematic Review and Meta-Analysis of Food Insecurity and Dyslipidemia. Journal of the American Board of Family Medicine : JABFM 2022. link 19 Khoury M, Bigras JL, Cummings EA, Harris KC, Hegele RA, Henderson M et al.. The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update. The Canadian journal of cardiology 2022. link 20 Koskinas KC, Catapano AL, Baigent C, Tokgozoglu L, Mach F. Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. European journal of preventive cardiology 2022. link 21 Rai A, Karki S, Prasad Sah S, Narayan Kamat L, Pradhan M. Dyslipidemia in Patients with Xanthelasma Palpebrarum Visiting the Department of Dermatology of a Tertiary Care Centre: A Descriptive Cross-sectional Study. JNMA; journal of the Nepal Medical Association 2022. link 22 Adel Mehraban MS, Tabatabaei-Malazy O, Rahimi R, Daniali M, Khashayar P, Larijani B. Targeting dyslipidemia by herbal medicines: A systematic review of meta-analyses. Journal of ethnopharmacology 2021. link 23 Sharba ZF, Shareef RH, Abd BA, Hameed EN. Association between Dyslipidemia and Vitamin D Deficiency: a Cross-Sectional Study. Folia medica 2021. link 24 Umeda T, Hayashi A, Fujimoto G, Piao Y, Matsui N, Tokita S. Medication Adherence/Persistence and Demographics of Japanese Dyslipidemia Patients on Statin-Ezetimibe as a Separate Pill Combination Lipid-Lowering Therapy　- An Observational Pharmacy Claims Database Study. Circulation journal : official journal of the Japanese Circulation Society 2019. link 25 Gosho M. Rhabdomyolysis risk from the use of two-drug combination of antidyslipidemic drugs with antihypertensive and antidiabetic medications: a signal detection analysis. Fundamental & clinical pharmacology 2019. link 26 Kalra S. Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibition: A Lipocrinologic Review. The Journal of the Association of Physicians of India 2018. link 27 Ray S, Sawhney JPS, Das MK, Deb J, Jain P, Natarajan S et al.. Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients - A consensus document. Indian heart journal 2018. link 28 Bucheit JD, Helsing H, Nadpara P, Virani SS, Dixon DL. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Journal of clinical lipidology 2018. link 29 Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ et al.. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARY. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2017. link 30 Chen C, Ge S, Li S, Wu L, Liu T, Li C. The Effects of Dietary Calcium Supplements Alone or With Vitamin D on Cholesterol Metabolism: A Meta-Analysis of Randomized Controlled Trials. The Journal of cardiovascular nursing 2017. link 31 Anguita Sánchez M, Castro Conde A, Cordero Fort A, García-Moll Marimón X, Gómez Doblas JJ, González-Juanatey JR et al.. Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology. Revista espanola de cardiologia (English ed.) 2016. link 32 Al Rasadi K, Almahmeed W, AlHabib KF, Abifadel M, Farhan HA, AlSifri S et al.. Dyslipidaemia in the Middle East: Current status and a call for action. Atherosclerosis 2016. link 33 Schamroth C. Adverse effects of the 'Noakes' diet on dyslipidaemia. Cardiovascular journal of Africa 2014. link 34 Palazón-Bru A, Gil-Guillén VF, Orozco-Beltrán D, Pallarés-Carratalá V, Valls-Roca F, Sanchís-Domenech C et al.. Is the physician's behavior in dyslipidemia diagnosis in accordance with guidelines? Cross-sectional ESCARVAL study. PloS one 2014. link 35 Sliż D, Filipiak KJ, Naruszewicz M, Siebert J, Mamcarz A. Standards of statin usage in Poland in high-risk patients: 3ST-POL study results. Kardiologia polska 2013. link 36 Sashidhara KV, Kumar A, Kumar M, Sonkar R, Bhatia G, Khanna AK. Novel coumarin derivatives as potential antidyslipidemic agents. Bioorganic & medicinal chemistry letters 2010. link 37 Brown AS, Cofer-Chase L, Eagan CA. Linguistic analysis of in-office dialogue among cardiologists, primary care physicians, and patients with mixed dyslipidemia. The American journal of cardiology 2010. link 38 Zappalla FR. Evaluation of dyslipidemia in children. Pediatric annals 2006. link 39 Shanahan RL, Kerzee JA, Sandhoff BG, Carroll NM, Merenich JA. Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization. Pharmacotherapy 2005. link 40 Reamy BV, Thompson PD. Lipid disorders in athletes. Current sports medicine reports 2004. link 41 Pillarisetti S, Saxena U. Lipoprotein lipase as a therapeutic target for dyslipidemia. Frontiers in bioscience : a journal and virtual library 2003. link 42 Korol AM, Rasia R. Signatures of deterministic chaos in dyslipidemic erythrocytes under shear stress. Chaos (Woodbury, N.Y.) 2003. link 43 Kalmansohn RB, Kalmansohn RW, Schiff DL. Present status of HMG reductase inhibitors in treatment of dyslipidemia. Angiology 1998. link 44 Demant T, Packard CJ. Studies of apolipoprotein B-100 metabolism using radiotracers and stable isotopes. European journal of pediatrics 1997. link 45 Baker AL, Roberts C, Gothing C. Dyslipidemias in childhood. An overview. The Nursing clinics of North America 1995. link 46 Farmer JA, Gotto AM. Currently available hypolipidaemic drugs and future therapeutic developments. Bailliere's clinical endocrinology and metabolism 1995. link80177-4) 47 Knoetgen U, Petek W, Kostner G. Alteration of serum lipid values and lipoproteins by bacteria as a possible cause of artifacts in the screening of dyslipoproteinemias. Klinische Wochenschrift 1976. link

Dysglycemia